The cell and gene therapy manufacturing services market share is expected to witness significant growth in the coming years. With the increasing prevalence of chronic diseases and genetic disorders, there is a growing demand for advanced therapies that can provide long-term solutions. This has led to a surge in research and development activities in the field of cell and gene therapy.

Manufacturing services play a crucial role in the commercialization of these therapies. As companies strive to bring their innovative treatments to market, they often rely on specialized manufacturing partners who possess the necessary expertise, infrastructure, and regulatory compliance to ensure safe and efficient production.

Currently, the market is dominated by a few key players who have established themselves as leaders in providing cell and gene therapy manufacturing services. These companies have invested heavily in state-of-the-art facilities equipped with cutting-edge technologies such as automation, closed systems, and single-use bioreactors. This enables them to meet the stringent quality standards required for cell and gene therapy production.

The Cell & Gene Therapy Manufacturing Services Market Size was valued at USD 16.92 billion in 2022 and is expected to reach USD 30.86 billion by 2030, and grow at a CAGR of 7.8% over the forecast period 2023-2030.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/1187

KEY MARKET SEGMENTATION:

By Therapy Type

• Gene Therapy Manufacturing
• Cell Therapy Manufacturing
  • Non-Stem Cell Therapy
  • Stem Cell Therapy

By Scale Type

• Commercial Scale Manufacturing
• Pre-commercial/ R&D Scale Manufacturing

By Mode type

• In-house Manufacturing
• Contract Manufacturing

By Workflow type

• Cell Processing
• Fill & Finish Operations
• Vector Production
• Analytical And Quality Testing
• Cell Banking
• Process Development
• Raw Material Testing
• Others 

Some of the major key players are as follows: Merck KGaA, Thermo Fisher Scientific, Catalent Inc., Lonza, Takara Bio Inc., Wuxi Advanced Therapies, F. Hoffmann-La Roche Ltd, Samsung Biologics, Bluebird Bio Inc., Novartis AG, Boehringer Ingelheim, Hitachi Chemical Co., Ltd., Miltenyi Biotec, Cellular Therapeutics.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com